Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $91.4952W HIGH $156.92
Volume
6.51 M
Value Traded
958.21 M
Short % Float
1.08%
Days to Cover
2.4
-0.67%Week
+1.77%1 Month
+8.67%3 Month
+31.27%6 Month
+60.61%5 Year
+8,098.03%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
364.26 B
EPS (TTM)
0.99
P/E Ratio
148.50
Ent. Value
402.70 B
Total Shares
2.47 B
Float Shares
2.46 B
Insiders
0.10%
Institutions
82.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MRK Catalyst Timeline
Dated clinical, regulatory and corporate events for Merck & Company, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Merck & Company, Inc.
566Total events
28Upcoming
326Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Secondary Endpoint DataEfinopegdutideClinical Data
Meaningful fibrosis improvement (≥1 stage without worsening of steatohepatitis) at Week 52 with efinopegdutide
MASH with stage F2 or F3 liver fibrosissource ↗
▲Primary Endpoint MetEfinopegdutideClinical Data
Efinopegdutide met primary endpoint of MASH resolution without worsening of fibrosis at 52 weeks in Phase 2b MK-6024-013
MASH with stage F2 or F3 liver fibrosissource ↗
▲Late-BreakerEfinopegdutidePresentation
Efinopegdutide Phase 2b results presented in late-breaking abstract session at The Liver Meeting in Denver
MASH with stage F2 or F3 liver fibrosissource ↗
●Safety Data UpdateEfinopegdutideClinical Data
Safety data from Phase 2b MK-6024-013 for efinopegdutide
MASH with stage F2 or F3 liver fibrosissource ↗
▲PublicationEfinopegdutidePresentation
Phase 2b efinopegdutide results published in The Lancet
MASH with stage F2 or F3 liver fibrosissource ↗
●Trial InitiationOHTUVAYREApprovedTrial
Merck initiates Phase 3 ENHANCE-3 trial of OHTUVAYRE for prevention of COPD exacerbations
COPD exacerbationssource ↗
●Enrollment UpdateOHTUVAYREApprovedTrial
Recruitment begins and first patients enrolling in ENHANCE-3 in the United States
COPD exacerbationssource ↗
▲Primary Endpoint MetPembrolizumabApprovedClinical Data
KEYNOTE-C93 met primary PFS endpoint, 43% reduction in risk of progression or death vs chemotherapy
mismatch repair deficient (dMMR) advanced or recurrent endometrial cancersource ↗
▲FDA Filing Acceptedsac-TMTFiledRegulatory Filing
FDA accepted for priority review the BLA for sac-TMT in previously treated endometrial cancer
advanced or recurrent endometrial cancersource ↗
▲Topline Readoutsac-TMTFiledClinical Data
TroFuse-005 interim analysis topline results presented at ESMO 2026 Presidential Symposium
advanced or recurrent endometrial cancersource ↗
▲Primary Endpoint Metsac-TMTFiledClinical Data
TroFuse-005 met dual primary endpoints of OS (HR=0.68) and PFS (HR=0.59) vs chemotherapy
advanced or recurrent endometrial cancersource ↗
▲Late-BreakerPembrolizumabApprovedPresentation
Late-breaking KEYNOTE-C93 results presented at ESMO 2026 Presidential Symposium (LBA12)
dMMR advanced or recurrent endometrial cancersource ↗
▲Oral Presentationsac-TMTFiledPresentation
TroFuse-005 data presented in Presidential Symposium at ESMO Congress 2026 (LBA11)
advanced or recurrent endometrial cancersource ↗
▲Priority Reviewsac-TMTFiledRegulatory Filing
FDA granted priority review to the sac-TMT BLA in endometrial cancer
advanced or recurrent endometrial cancersource ↗
▲PublicationPembrolizumabApprovedPresentation
KEYNOTE-C93 results published simultaneously in The Lancet
dMMR advanced or recurrent endometrial cancersource ↗
▲Publicationsac-TMTFiledPresentation
TroFuse-005 results published simultaneously in The Lancet
advanced or recurrent endometrial cancersource ↗
▲Primary Endpoint Metintismeran autogeneClinical Data
INTerpath-001 met primary RFS endpoint (HR=0.58, p<0.001)
completely resected stage IIB-IV melanoma (adjuvant)source ↗
▲Topline Readoutintismeran autogeneClinical Data
INTerpath-001 Phase 3 topline RFS/DMFS results announced
completely resected stage IIB-IV melanoma (adjuvant)source ↗
▲EU ApprovalPembrolizumabApprovedEx-US Regulatory
EC approves KEYTRUDA plus Padcev as perioperative treatment for resectable MIBC
resectable muscle-invasive bladder cancer (MIBC)source ↗
▲Manufacturing MilestoneCMC / Inspection
Merck inaugurates ADVANCE bioanalytical research facility at West Point, PA campus
●Oral PresentationremigromigPresentation
One-year BRUNELLO results presented at AAO 2026 in New Orleans
diabetic macular edema (DME)source ↗
▼Safety Data UpdateremigromigClinical Data
BRUNELLO one-year safety data: increased PDR-related AEs and discontinuations with remigromig
diabetic macular edema (DME)source ↗
▲Primary Endpoint MetremigromigClinical Data
BRUNELLO met primary endpoint: remigromig non-inferior to ranibizumab in BCVA at one year
diabetic macular edema (DME)source ↗
▼Secondary Endpoint DataremigromigClinical Data
No secondary endpoints demonstrated superiority to ranibizumab in BRUNELLO
diabetic macular edema (DME)source ↗
◆Topline Readoutraludotatug deruxtecanClinical Data
Raludotatug deruxtecan plus bevacizumab in platinum-resistant recurrent ovarian cancer: cohort B-1 results from Phase 1b/2 REJOICE-Ovarian02 at ESMO 2026
platinum-resistant recurrent ovarian cancersource ↗
▲Topline Readoutintismeran autogeneClinical Data
First presentation of pivotal Phase 3 INTerpath-001 data for intismeran autogene plus KEYTRUDA in adjuvant melanoma at ESMO 2026 Presidential Symposium
completely resected stage IIB-IV melanoma (adjuvant)source ↗
◆Topline ReadoutPembrolizumabApprovedClinical Data
NRG-GY020: Phase 3 randomized trial of radiation +/- pembrolizumab for newly diagnosed early-stage HIR dMMR endometrioid endometrial cancer at ESMO 2026
newly diagnosed early-stage high intermediate risk mismatch repair deficient endometrioid endometrial cancersource ↗
◆Topline ReadoutWELIREGApprovedClinical Data
Final analysis of Phase 3 LITESPARK-011: belzutifan plus lenvatinib versus cabozantinib for advanced RCC after anti-PD-(L)1 therapy at ESMO 2026
advanced renal cell carcinoma after anti-PD-(L)1 therapysource ↗
▲Topline Readoutsac-TMTFiledClinical Data
First presentation of pivotal Phase 3 TroFuse-005 data for sac-TMT in advanced/recurrent endometrial cancer at ESMO 2026 Presidential Symposium
advanced or recurrent endometrial cancersource ↗
●Biomarker DataClinical Data
ctDNA analysis of Phase 3 KEYNOTE-B15: neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in cisplatin-eligible MIBC at ESMO 2026
muscle-invasive bladder cancer (MIBC)source ↗
●Poster Presentationsac-TMTFiledPresentation
Sac-TMT plus pembrolizumab in post-platinum advanced pMMR endometrial cancer: Phase 2 results at ESMO 2026
post-platinum advanced mismatch repair proficient endometrial cancersource ↗
◆Topline ReadoutClinical Data
Long-term follow-up analysis from EV-103 cohorts DE/A and K of enfortumab vedotin with or without pembrolizumab in 1L cisplatin-ineligible la/mUC at ESMO 2026
cisplatin-ineligible locally advanced or metastatic urothelial carcinomasource ↗
●Subgroup AnalysisPembrolizumabApprovedClinical Data
Ad hoc analysis from KEYNOTE-905 of perioperative pembrolizumab or enfortumab vedotin plus pembrolizumab in cisplatin-ineligible MIBC at ESMO 2026
muscle-invasive bladder cancer (MIBC)source ↗
●Poster PresentationPembrolizumabApprovedPresentation
Association between disease control and patient-reported functioning and quality of life in ASCENT-04/KEYNOTE-D19 at ESMO 2026
triple negative breast cancersource ↗
●Poster Presentationintismeran autogenePresentation
Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: Phase 1 results at ESMO 2026
resectable pancreatic ductal adenocarcinomasource ↗
◆Oral PresentationPembrolizumabApprovedPresentation
First presentation of Phase 3 KEYNOTE-C93 data for first-line KEYTRUDA monotherapy in dMMR advanced/recurrent endometrial cancer
mismatch repair deficient (dMMR) advanced or recurrent endometrial cancersource ↗
◆Oral Presentationintismeran autogenePresentation
First presentation of pivotal Phase 3 INTerpath-001 data for intismeran autogene plus KEYTRUDA in adjuvant melanoma
completely resected stage IIB-IV melanoma (adjuvant)source ↗
◆Oral Presentationraludotatug deruxtecanPresentation
Raludotatug deruxtecan plus bevacizumab in PROC: cohort B-1 results from Phase 1b/2 REJOICE-Ovarian02
platinum-resistant recurrent ovarian cancersource ↗
◆Oral Presentationsac-TMTFiledPresentation
Final OS analysis of sac-TMT versus chemotherapy in previously treated TNBC (OptiTROP-Breast01)
previously treated locally recurrent or metastatic triple-negative breast cancersource ↗
◆Oral PresentationWELIREGApprovedPresentation
Final analysis results from Phase 3 LITESPARK-011 for WELIREG plus LENVIMA in advanced RCC
advanced renal cell carcinoma with a clear cell componentsource ↗
◆Poster Presentationraludotatug deruxtecanPresentation
Updated analysis of raludotatug deruxtecan in PROC from Phase 2 part of REJOICE-Ovarian01
platinum-resistant ovarian cancersource ↗
◆Oral PresentationPresentation
Long-term follow-up of enfortumab vedotin with or without pembrolizumab in 1L cisplatin-ineligible la/mUC (EV-103 cohorts DE/A and K)
cisplatin-ineligible locally advanced or metastatic urothelial carcinomasource ↗
▲Late-Breakerintismeran autogenePresentation
INTerpath-001 results selected as ESMO 2026 Presidential Symposium late-breaker (LBA1)
completely resected stage IIB-IV melanoma (adjuvant)source ↗
▲Topline ReadoutClinical Data
First-time pivotal Phase 3 INTerpath-001 data for intismeran autogene plus KEYTRUDA presented at ESMO Congress 2026
resected Stage IIB-IV melanoma (adjuvant)source ↗
▲Topline Readoutsac-TMTFiledClinical Data
First-time pivotal Phase 3 TroFuse-005 data for sac-TMT presented at ESMO Congress 2026
advanced or recurrent endometrial cancersource ↗
▲Full ResultsClinical Data
First-time pivotal Phase 3 TroFuse-005 data for sac-TMT presented at ESMO Congress 2026
advanced or recurrent endometrial cancersource ↗
▲Late-BreakerTulisokibartPresentation
Tulisokibart Phase 2b HS results presented in Late-Breaking News session at EADV 2026
moderate to severe hidradenitis suppurativa (HS)source ↗
▲Secondary Endpoint DataTulisokibartClinical Data
Key secondary endpoints showed numerical improvement over placebo in Phase 2b HS trial
Moderate to severe hidradenitis suppurativa (HS)source ↗
▲Primary Endpoint MetTulisokibartClinical Data
Tulisokibart met primary endpoint of HiSCR50 at week 16 in Phase 2b HS trial
Moderate to severe hidradenitis suppurativa (HS)source ↗
Past FDA Catalysts and PDUFA Decisions
How MRK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-08 | Alimatravir (AMI; MK-8527) | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
90
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 1 of 687)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Keytruda | |||
| Gardasil/Gardasil | |||
| Livestock | |||
| Companion Animal | |||
| ProQuad MMR II Varivax | |||
| Winrevair | |||
| Bridion | |||
| Keytruda Qlex | |||
| Prevymis | |||
| Januvia | |||
| Welireg | |||
| Capvaxive |
Top 12 of 22 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8527 Small MoleculesNCT07044297 | Human Immunodeficiency Virus | Phase 3 | ACTIVE NOT_RECRUITING | 9,035 | Jul 22, 2027 | ||||||
| Alimatravir Small MoleculesNCT07850609 | HIV | Phase 2 | RECRUITING | 80 | Dec 2, 2027 | ||||||
| Calderasib Small MoleculesNCT06997497 | Colon Adenocarcinoma | Phase 3 | RECRUITING | 477 | Oct 27, 2030 | ||||||
| Calderasib Small MoleculesNCT07286149 | Lung Neoplasm Malignant | Phase 1/2 | RECRUITING | 140 | Apr 13, 2032 | ||||||
| Calderasib Small MoleculesNCT07252739 | Malignant Neoplasm | Phase 2 | RECRUITING | 290 | May 31, 2032 | ||||||
| Calderasib Small MoleculesNCT05067283 | Advanced Solid Tumors | Phase 1 | RECRUITING | 830 | Feb 25, 2030 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06203210 | Small Cell Lung Cancer | Phase 3 | RECRUITING | 540 | Dec 1, 2029 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06644781 | Esophageal Squamous Cell Carcinoma | Phase 3 | RECRUITING | 510 | Nov 1, 2029 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06925737 | Prostate Cancer | Phase 3 | RECRUITING | 1,440 | Jan 6, 2031 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT07405151 | Oesophageal Squamous Cell Carcinoma | Phase 1/2 | RECRUITING | 60 | Jun 12, 2028 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06362252 | Extensive Stage-small Cell Lung Cancer | Phase 1/2 | RECRUITING | 123 | Feb 20, 2028 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06330064 | Recurrent or Metastatic Solid Tumors | Phase 1/2 | RECRUITING | 680 | Jul 25, 2028 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT04145622 | Advanced Solid Tumor | Phase 1/2 | ACTIVE NOT_RECRUITING | 247 | Oct 31, 2029 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT06863272 | Castration-Resistant Prostatic Cancer | Phase 1/2 | RECRUITING | 360 | Oct 1, 2031 | ||||||
| Ifinatamab Deruxtecan Antibody-Drug Conjugates (ADCs)NCT07630974 | Malignant Neoplasm | Phase 1/2 | RECRUITING | 134 | Aug 17, 2031 | ||||||
| ISL Small MoleculesNCT06891066 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 2/3 | ACTIVE NOT_RECRUITING | 720 | Sep 30, 2031 | ||||||
| Gocatamig BiologicsNCT04471727 | Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,123 | Jan 28, 2028 | ||||||
| Gocatamig BiologicsNCT07227597 | Small Cell Lung Cancer Extensive Stage | Phase 1/2 | RECRUITING | 170 | Dec 30, 2030 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT05933577 | Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 1,089 | Sep 26, 2030 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT06077760 | Non-small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,744 | Dec 21, 2035 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT06833073 | Urinary Bladder Neoplasms | Phase 2 | RECRUITING | 308 | Sep 3, 2031 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT07221474 | Squamous Non-small Cell Lung Cancer | Phase 2 | RECRUITING | 180 | May 6, 2031 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT06307431 | Renal Cell Carcinoma | Phase 2 | ACTIVE NOT_RECRUITING | 272 | Jun 8, 2032 | ||||||
| Intismeran autogene RNA-Based TherapiesNCT06961006 | Malignant Melanoma | Phase 2 | ACTIVE NOT_RECRUITING | 160 | Sep 5, 2031 | ||||||
| Opevesostat Small MoleculesNCT06136650 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | RECRUITING | 1,314 | Dec 2, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every MRK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| efinopegdutide Fast Track | metabolic dysfunction-associated steatohepatitis (MASH) and stage 2-3 fibrosis | Phase 2b | 2026-11-09 | MASH resolution: 4 mg 56% (p<0.0001), 7 mg 63% (p<0.0001), 10 mg 61% (p<0.0001), placebo 13%; fibrosis improvement: 4 mg 43%, 7 mg 52%, 10 mg 34%, placebo 21%; nausea: 4 mg 29%, 7 mg 39%, 10 mg 44%, semaglutide 39%, placebo 11%; diarrhea: 4 mg 29%, 7 mg 26%, 10 mg 22%, semaglutide 22%, placebo 20%; vomiting: 4 mg 20%, 7 mg 8%, 10 mg 28%, semaglutide 15%, placebo 3%; discontinuations due to adverse events: 4 mg 3%, 7 mg 4%, 10 mg 11%, semaglutide 1%, placebo 1%Read More | Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 FibrosisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Guindo ChirfiOfficer (EVP, Access, Policy & Comms) | Sell | -10,000 36,613.127 held | $135.00 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MRK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.6 % | 85.25 M | 663.40 K |
Ownership Trends
MRK Short Interest
Shares sold short, counted twice a month.
1.08%
Short % of Float
of tradable shares sold short
26.6M
Shares Sold Short
-0.8% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
11.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MRK ranks across every disease it competes in
Competitive Position is a premium feature
See how MRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMRK News
MRK▲ +0.6%today
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck received a positive opinion from the EU CHMP to expand ENFLONSIA's indication for preventing severe RSV disease in children up to 24 months. This recommendation will be reviewed by the European Commission, with a decision expected in two months. ENFLONSIA is the first preventive option for RSV administered without weight-based dosing.
Read more →MRK▲ +0.6%today
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck received a positive opinion from the EU CHMP recommending approval of WELIREG (belzutifan) in combination with lenvatinib for adults with advanced renal cell carcinoma. This regimen demonstrated a significant improvement in progression-free survival in the Phase 3 LITESPARK-011 trial. A final decision from the European Commission is expected within two months.
Read more →MRK▲ +0.6%today
Merck to Participate in the Jefferies Global Healthcare Conference in London
Merck announced that Dr. Eliav Barr will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2026. The event will be accessible via a live audio webcast for investors, analysts, and the public. This engagement highlights Merck's commitment to transparency and communication with stakeholders.
Read more →MRK▲ +0.6%today
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
The U.S. FDA has approved PIMJETMI® (pimicotinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT). This approval follows prior approvals in China, Canada, and Switzerland, enhancing global access. The treatment demonstrated significant improvements in tumor response and quality of life metrics in clinical trials. Abbisko Therapeutics will receive a milestone payment and royalties from Merck KGaA.
Read more →MRK▲ +0.6%today
Philip Seo, MD, Named Editor-in-Chief of The Merck Manuals
Merck Manuals announced the appointment of Philip Seo, MD, as Editor-in-Chief. Dr. Seo aims to enhance the resource's trusted medical information for both healthcare professionals and patients. The Manuals, available in 16 languages, continue to expand their digital offerings, including videos and interactive models, while remaining free of charge.
Read more →MRKMerck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Merck announced positive results from its Phase 2b trial of efinopegdutide for adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage 2-3 fibrosis. The trial demonstrated significant MASH resolution and improvements in liver fibrosis at 52 weeks. Results were presented at The Liver Meeting and published in The Lancet, indicating efinopegdutide's potential as a treatment option.
Read more →MRKMerck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Merck has initiated the ENHANCE-3 Phase 3 trial to evaluate OHTUVAYRE (ensifentrine) for preventing COPD exacerbations in adults. The trial will enroll approximately 2,136 patients across 28 countries, focusing on the annualized rate of moderate or severe exacerbations. OHTUVAYRE is the first new inhaled therapy for COPD in over 20 years, combining bronchodilation and anti-inflammatory effects.
Read more →MRKMerck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Merck will present new data on its HIV treatment and prevention pipeline at HIV Glasgow 2026. Key highlights include Phase 3 analyses of the investigational once-weekly oral combination of islatravir/lenacapavir and patient-reported outcomes for IDVYNSO. The presentations will emphasize Merck's strategy to enhance oral treatment options for HIV.
Read more →MRKMerck Manuals Helps Patients Navigate the Different Types of Sunscreens
Merck Manuals released an editorial discussing various sunscreen types, emphasizing the recent FDA approval of bemotrizinol. This ingredient offers effective UVA and UVB protection and is more stable in sunlight. The editorial also provides important tips for sunscreen application to enhance skin safety.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Merck & Co. reported third-quarter 2026 financial results, with total sales of $18.1 billion, a 5% increase. Key products like KEYTRUDA and WINREVAIR showed strong growth, with sales of $8.6 billion and $694 million, respectively. However, GAAP net income fell by 12%, and non-GAAP EPS decreased to $2.49. The company also highlighted significant advancements in its oncology pipeline.
Read more →MRKKEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
Merck announced positive results from the Phase 3 KEYNOTE-C93 trial, showing KEYTRUDA (pembrolizumab) as monotherapy reduced the risk of disease progression or death by 43% in patients with dMMR advanced or recurrent endometrial cancer. The median progression-free survival was 38.2 months, significantly longer than the 8.4 months seen with chemotherapy. These results will be presented at the ESMO Congress 2026.
Read more →MRKSacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Merck announced positive results from the Phase 3 TroFuse-005 trial of sacituzumab tirumotecan (sac-TMT) for advanced endometrial cancer. The trial showed a 32% reduction in death risk and a 41% reduction in disease progression risk compared to chemotherapy. The FDA has accepted a Biologics License Application for priority review.
Read more →MRKMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck and Moderna reported positive results from the Phase 3 INTerpath-001 trial, showing that intismeran combined with KEYTRUDA significantly reduces the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma. The combination therapy demonstrated a 42% reduction in risk compared to KEYTRUDA alone, with even greater benefits observed after six months. The findings will be presented at the ESMO Congress 2026.
Read more →MRKMerck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
Merck has partnered with NVIDIA, Microsoft, and Dawn Health to create an innovative Patient Support Program for individuals with rare tumors. This collaboration focuses on utilizing AI technology to deliver personalized and continuous support, particularly for patients with desmoid tumors and neurofibromatosis type 1. The program aims to address the complex treatment pathways and high unmet needs in these patient populations.
Read more →MRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
The European Commission has approved KEYTRUDA® (pembrolizumab) in combination with Padcev® (enfortumab vedotin-ejfv) for adults with resectable muscle-invasive bladder cancer (MIBC). This marks the first PD-1 inhibitor plus antibody-drug conjugate regimen available in the EU for MIBC patients, regardless of cisplatin eligibility. The approval is based on positive results from the Phase 3 KEYNOTE-B15 trial.
Read more →MRKMerck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck has inaugurated its ADVANCE bioanalytical facility in West Point, Pennsylvania, with a $550 million investment aimed at enhancing its research and development capabilities. The facility will streamline the analysis of biological samples and support a diverse pipeline of clinical programs. This expansion is part of Merck's broader commitment to domestic manufacturing and innovation in the life sciences sector.
Read more →MRKPaul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Merck & Co., Inc. has elected Paul J. Diaz to its Board of Directors, effective November 1, 2026. Diaz, a managing partner at Cressey & Company, has significant experience in the healthcare sector, previously serving as CEO of Myriad Genetics and Kindred Healthcare. He will be up for election by shareholders in May 2027.
Read more →MRKMerck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck (MRK) announced the presentation of first-time pivotal Phase 3 results for its oncology pipeline at the ESMO 2026 Congress. Key studies include the INTerpath-001 trial showing improved survival rates for melanoma patients treated with intismeran autogene plus KEYTRUDA, and the TroFuse-005 trial demonstrating efficacy in advanced endometrial cancer. The company also highlighted its extensive oncology portfolio with over 90 abstracts to be presented.
Read more →MRKMerck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Merck presented one-year results from the pivotal Phase 2b/3 BRUNELLO study, showing that remigromig, a novel tri-specific antibody, achieved non-inferior visual acuity compared to ranibizumab in diabetic macular edema patients. While both doses were well tolerated, remigromig was associated with higher rates of proliferative diabetic retinopathy. The findings support further evaluation of this new treatment approach.
Read more →MRKMerck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Merck will conduct a conference call on October 29, 2026, to discuss its sales and earnings for the third quarter. This event aims to provide insights into the company's financial performance and future outlook. Stakeholders and investors are encouraged to participate for detailed updates.
Read more →About Merck & Company, Inc.
Headquarters126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
BIOPHARMAWATCH ELITE
Trade the next MRK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime